Jutte van der Werff Ten Bosch

Jutte van der Werff Ten Bosch

Auto-generated profile, based on publicly available information

Jutte van der Werff Ten Bosch

Department of Paediatrics, UZ Brussel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
PGPiotr Grabowski
Piotr Grabowski
SHSebastian Hesse
Sebastian Hesse
SHSebastian Hollizeck
Sebastian Hollizeck
MRMeino Rohlfs
Meino Rohlfs
UBUta Behrends
Uta Behrends
JRJuri Rappsilber
Juri Rappsilber
Neutrophil granulocytes are critical mediators of innate immunity and tissue regeneration. Rare diseases of neutrophil granulocytes may affect their differentiation and/or functions. However, there are very few validated diagnostic tests assessing the functions of neutrophil granulocytes in these diseases. Here, we set out to probe omics analysis as a novel diagnostic platform for patients with defective differentiation and function of neutrophil granulocytes. We analyzed highly purified neutrophil granulocytes from 68 healthy individuals and 16 patients with rare monogenic diseases. Cells were isolated from fresh venous blood (purity >99%) and used to create a spectral library covering almost 8000 proteins using strong cation exchange fractionation. Patient neutrophil samples were then analyzed by data-independent acquisition proteomics, quantifying 4154 proteins in each sample. Neutrophils with mutations in the neutrophil elastase gene ELANE showed large proteome changes that suggest these mutations may affect maturation of neutrophil granulocytes and initiate misfolded protein response and cellular stress mechanisms. In contrast, only few proteins changed in patients with leukocyte adhesion deficiency (LAD) and chronic granulomatous disease (CGD). Strikingly, neutrophil transcriptome analysis showed no correlation with its proteome. In case of two patients with undetermined genetic causes, proteome analysis guided the targeted genetic diagnostics and uncovered the underlying genomic mutations. Data-independent acquisition proteomics may help to define novel pathomechanisms in neutrophil diseases and provide a clinically useful diagnostic dimension. Graphical Abstract Highlights Data-independent acquisition proteomics analysis of naive neutrophils from patients with rare monogenic diseases. Proteomics analysis helps guide targeted genetic diagnostics of patients for which routine clinical diagnostics proved inconclusive.

1 November 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MVMirjam Esther van de Velde
Mirjam Esther van de Velde
MBMarleen. H. van Den Berg
Marleen. H. van Den Berg
Gertjan KaspersGertjan Kaspers
Gertjan Kaspers
FAFloor C. H. Abbink
Floor C. H. Abbink
JTJos Twisk
Jos Twisk
RLRaphaële R. L. van Litsenburg
Raphaële R. L. van Litsenburg
Purpose: Vincristine (VCR) is a chemotherapeutic agent used in the treatment of pediatric oncology patients, but its main toxicity is VCR‐induced peripheral neuropathy (VIPN). However, whether VIPN has an effect on health‐related quality of life (HR‐QoL) in children during treatment is unknown. Therefore, the aim of our study was to investigate the association between VIPN and HR‐QoL in children starting treatment for cancer.Methods: Measurements of VIPN were performed using two tools: Common Terminology Criteria for Adverse Events (CTCAE) and pediatric‐modified Total Neuropathy Score (ped‐mTNS). Assessment of HR‐QoL was done with self‐ and proxy assessment of the Cancer and Generic module of the Pediatric Cancer Quality of Life Inventory™ (PedsQL).Results: In total, N = 86 children were included. HR‐QoL of children with VIPN (n = 67%, 76%) was significantly lower in comparison with children without VIPN: estimated Total score of PedsQL Generic (proxy) 84.57; β = −8.96 and 95% confidence interval (CI) −14.48 to −3.43; p = 0.002, estimated PedsQL Generic Total score (self‐reported): 85.16, β = −8.38 (95% CI: −13.76 to −3.00); p = 0.003. Similar results were found in the Pain and Hurt domain of the PedsQL Cancer (pain: estimated score [proxy]: 85.28, β = −9.94 [95%CI: −16.44 to −3.45], p = 0.003; hurt: estimated score [self‐report] 97.57, β = −19.15 [95%CI: −26.82 to −11.48], p < 0.001).Conclusion: VIPN results in a significant reduction of HR‐QoL in children under treatment for a malignancy, which means that VIPN is important for the well‐being of pediatric oncology patients. Therefore, this study underlines the importance of optimizing treatment with VCR, thereby aiming to reduce VIPN while maintaining efficacy.

14 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
APAgata Pastorczak
Agata Pastorczak
AAAndishe Attarbaschi
Andishe Attarbaschi
SBSimon Bomken
Simon Bomken
ABArndt Borkhardt
Arndt Borkhardt
JBJutte van der Werff Ten Bosch
Jutte van der Werff Ten Bosch
JLJan Loeffen
Jan Loeffen
Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.

7 January 2020 in Disability and Rehabilitation
Verified
Journal Article
Closed access
SVStephanie Vanclooster
Stephanie Vanclooster
KHKatelijne Van Hoeck
Katelijne Van Hoeck
LPLieve Peremans
Lieve Peremans
JBJohan Bilsen
Johan Bilsen
JBJutte Van Der Werff Ten Bosch
Jutte Van Der Werff Ten Bosch
AJAnna Jansen
Anna Jansen
Purpose: The purpose of this study was to describe experiences of childhood brain tumor survivors (CBTS) and key figures in their environment after returning to school, using the International Classification of Functioning, Disability and Health – Children and Youth framework. Methods: We conducted semi-structured interviews with five children, nine parents, 28 teachers, and 14 health professionals at three predetermined times over a two-year period. A qualitative content analysis was performed by linking meaningful units from transcribed interviews to ICF codes. Results: Children experienced diverse body dysfunctions that could impede school participation, mostly related to knowledge acquisition and application, executive functioning and social life. Support at school and professional aftercare were essential to alleviate the child’s difficulties. The teacher’s attitude, parental involvement, and practices of collaboration belonging to the child’s supportive network further influenced the reintegration process. Also, child-specific factors including emotional reactions to illness, age, and balance between school life and leisure time were considered to affect school readjustment. Conclusions: The International Classification of Functioning, Disability and Health framework is a useful instrument to systematically describe experiences of CBTS and key figures regarding school life, providing a common language to communicate for stakeholders in education and healthcare following the child’s return.

7 April 2009 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JBJutte E. van der Werff Ten Bosch
Jutte E. van der Werff Ten Bosch
WKWouter J.W. Kollen
Wouter J.W. Kollen
LBLynne M. Ball
Lynne M. Ball
DBDanielle M.C. Brinkman
Danielle M.C. Brinkman
AVAnn Vossen
Ann Vossen
RBRobbert G.M. Bredius
Robbert G.M. Bredius

1 December 2016 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
JBJutte van der Werff Ten Bosch
Jutte van der Werff Ten Bosch
MAMachiel van Den Akker
Machiel van Den Akker